Hi-Tech Pharmacal gets tentative nod for nail fungus treatment
April 17 (Reuters) - Hi-Tech Pharmacal Co. Inc. (HITK.O: Quote, Profile, Research, Stock Buzz) said the U.S. Food and Drug Administration tentatively approved its Ciclopirox, which is the generic equivalent of Dermik Laboratories' Penlac nail fungus treatment.
Final approval is expected upon expiration of Penlac's patent on Sept. 18, the company said in a statement. (Reporting by Anant Vijay Kala in Bangalore)
© Thomson Reuters 2008 All rights reserved
Help us advance this story. Provide relevant links or share your insights using our comment box. Please be considerate and help us by reporting any abuse you find. Reuters will delete comments that don't meet community standards.
Have a correction to this article? Email the editors
Entertainment
Zardari Pakistan's new president